Article Versions Notes

Mukherjee S, Chakraborty M, Haubner J, Ernst G, DePasquale M, Carpenter D, Barrow JC, Chakraborty A. The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling. Biomolecules. 2023; 13(5):868. https://doi.org/10.3390/biom13050868

Mukherjee, Sandip, Molee Chakraborty, Jake Haubner, Glen Ernst, Michael DePasquale, Danielle Carpenter, James C. Barrow, and Anutosh Chakraborty. 2023. "The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling" Biomolecules 13, no. 5: 868. https://doi.org/10.3390/biom13050868

Mukherjee, S., Chakraborty, M., Haubner, J., Ernst, G., DePasquale, M., Carpenter, D., Barrow, J. C., & Chakraborty, A. (2023). The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling. Biomolecules, 13(5), 868. https://doi.org/10.3390/biom13050868